Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT).
about
Fibrates for type 2 diabetes mellitusFibrates for type 2 diabetes mellitusHypertriglyceridemia: its etiology, effects and treatmentUric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease?Which is the best lipid-modifying strategy in metabolic syndrome and diabetes: fibrates, statins or both?The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. [ISRCTN64783481]Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]Use of fibrates in the metabolic syndrome: A reviewOrigin and therapy for hypertriglyceridaemia in type 2 diabetesMitochondrial fatty acid oxidation alterations in heart failure, ischaemic heart disease and diabetic cardiomyopathyRole of lipotoxicity in endothelial dysfunctionUpdate on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association.Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statinsFenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a reviewPomegranate flower: a unique traditional antidiabetic medicine with dual PPAR-alpha/-gamma activator propertiesOverview of the metabolic syndrome; an emerging pandemic of public health significance.The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: II. Therapeutic management of atherogenic dyslipidemia.Modifications of coronary risk factors.Diabetes: managing dyslipidaemia.Triglycerides and HDL cholesterol: stars or second leads in diabetes?ABO blood group frequency in Ischemic heart disease patients in Pakistani population.Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndromeDoes combination therapy with statins and fibrates prevent cardiovascular disease in diabetic patients with atherogenic mixed dyslipidemia?Effects of combination lipid therapy in type 2 diabetes mellitus.Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus.Management of hypertriglyceridemia in the diabetic patientThe Role of PPARα Activation in Liver and Muscle.Diabetic cardiomyopathy: from the pathophysiology of the cardiac myocytes to current diagnosis and management strategiesCombination therapy of statins and fibrates in the management of cardiovascular risk.Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database.Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trialEfficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trialsPharmacokinetics, efficacy and safety of aleglitazar for the treatment of type 2 diabetes with high cardiovascular risk.Atherosclerosis in type 2 diabetes: a role for fibrate therapy?Impact of genetic and environmental factors on hsCRP concentrations and response to therapeutic agentsPURLs: Add a fibrate to a statin?The effect of bezafibrate and omega-3 fatty acids on lymphocyte cytokine release and systemic inflammation in patients with isolated hypertriglyceridemiaThe role of triglycerides in atherosclerosis.The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes.Hypertriglyceridemia-induced recurrent acute pancreatitis: A case-based review.
P2860
Q24195161-520DA033-6366-443A-AAB5-A67F98CD9D62Q24204016-9CB51AEF-AE28-47F7-9B22-8BBA58F60487Q24672914-214DE65F-1DAD-4DDA-90C4-AE80CA8E1BFFQ24678615-A050FFDF-F4CB-4DE8-BEF0-A5C871EF1B85Q24804259-9E6D6ED7-27E4-4B8E-BC58-E56DF9E16C3DQ24804541-9369DC32-1ED7-49C2-A3DE-266D2CDC102BQ24815913-BEE8D9B3-D821-4C3F-A9F9-53772D5D0A85Q26765234-3392BE4D-459F-4004-A440-5A2CE160B6C3Q26824004-8776694B-4AA4-4C19-AB21-E8EABDE96655Q26859582-BDEE6A3E-1820-4D63-8B13-F2FA3A599C11Q27000731-496A0A2C-7C66-4A10-A595-E5BE3E96D4A7Q27687851-1DBCEBF5-A581-4117-BFC6-D2C5E0C7855CQ28200554-254B188F-4437-4FBD-A746-8A442BD86D0AQ28220294-64F70BD9-D04D-4707-A502-DCC5EC9D9FB3Q28261771-17F33DB6-E870-4EF8-B3A1-61C918C52921Q30366107-9A7254A2-6F0D-44C4-B455-91190CDFA2B8Q30380628-37CA4A7B-4AA4-4922-A2D4-C9FD4C8AF7BFQ30439801-586B2214-30F4-4B97-B92A-FBEB124EBEB2Q33446544-D7371E8A-6B99-4CD1-B401-6661B70B32D3Q33610637-8FC53BC2-74CA-4E82-8193-293B775C574CQ33722617-1323AE72-CBF7-4FCB-A571-23F0DA798C86Q33736139-5F7F3F67-EAE6-45E5-B3DE-363B9EFC367FQ33776187-0DFD6DF9-486A-4A01-BE18-57BD8613732AQ33889260-A331A153-EC5F-4643-A0CD-FB0A0CA58E0AQ33933474-355E50EF-F176-46E0-ACCE-CCDC55F4A725Q33935729-545E1161-015B-4FCC-849C-26E701B62871Q34106233-8C9686EE-3E50-4127-8B45-3F4FA03D8059Q34245190-37B66F67-826E-4768-8AE9-DDE1DE4D438BQ34305993-DE514949-D625-4567-965A-C08AACE9633EQ34559971-FEEC5BCE-9B95-4821-9BC6-5293CE3406A3Q34571157-E60565CD-CCB3-47BD-B86A-1A17512820E1Q34601330-15C49217-D7ED-4D01-9680-27BD57BB7931Q34628781-86DB58AA-1D4F-4865-933F-2C7063204DB8Q34730108-4964F192-57FA-431F-B677-40D7D2F7FCB5Q34901492-7AD4855E-D4BB-4C4C-85D8-FA8794634C72Q35247278-A09A2B15-54D0-4B6A-A3DC-F824DB0592FEQ35332645-149C0D0F-3177-40D9-99B2-04F1E1B83C3BQ35602424-4821F22A-7EE4-4313-8F42-9661122EB7B2Q35640348-36AE2914-3545-44EE-BA6A-5867356CABC3Q35686315-07ADA98B-5F73-4794-B471-1C8F3DC368D9
P2860
Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT).
description
2002 nî lūn-bûn
@nan
2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Diabetes, plasma insulin, and ...... n intervention trial (VA-HIT).
@ast
Diabetes, plasma insulin, and ...... n intervention trial (VA-HIT).
@en
Diabetes, plasma insulin, and ...... n intervention trial (VA-HIT).
@nl
type
label
Diabetes, plasma insulin, and ...... n intervention trial (VA-HIT).
@ast
Diabetes, plasma insulin, and ...... n intervention trial (VA-HIT).
@en
Diabetes, plasma insulin, and ...... n intervention trial (VA-HIT).
@nl
prefLabel
Diabetes, plasma insulin, and ...... n intervention trial (VA-HIT).
@ast
Diabetes, plasma insulin, and ...... n intervention trial (VA-HIT).
@en
Diabetes, plasma insulin, and ...... n intervention trial (VA-HIT).
@nl
P2093
P921
P1476
Diabetes, plasma insulin, and ...... n intervention trial (VA-HIT).
@en
P2093
David B Nelson
Dorothea Collins
Ernst J Schaefer
Fred H Faas
Hanna Bloomfield Rubins
James W Anderson
Marshall B Elam
Sander J Robins
P304
P356
10.1001/ARCHINTE.162.22.2597
P407
P577
2002-12-01T00:00:00Z